Sourav Sinha is a 2023 Millennium fellow and the founding general partner and head of strategy at the Longevity Vision Fund, a venture fund investing in growth-stage biotechnology companies developing innovations aimed to extend the healthy human lifespan. Sinha also serves as the senior healthcare advisor for 10X Capital, where he leads investments and transactions into clinical-stage biotech companies.

Sinha is also a scientific co-founder of Codeable Therapeutics, which develops targeted therapies for cancer. He was a founding executive of Celularity, which develops transformative treatments for deadly cancers. Sinha is a global shaper of the World Economic Forum and was invited as an expert panelist of the Horasis Extraordinary Meetings on the United States and Asia. He serves on the Young Professionals Committee of Gabrielle’s Angel Foundation for Cancer Research.

Sinha holds a degree in molecular biology and biochemistry from Dartmouth College and is a graduate of Singularity University’s Global Solutions Program. His research has been published in top-tier journals and industry textbooks, and he was featured on the Forbes 30 Under 30 list for healthcare in 2018.